Novartis 1Q11 1Q Revenues: $14.0 billion (+16%) 1Q Earnings: $3.4 billion (+2%) Comments: Pharmaceuticals sales were up 7% to $7.8 billion. Diovan sales were down 3% to $1.4 billion. Exforge sales were $261 million (+28%). Tekturna/Rasilez sales were $131 million (+47%). Galvus sales were up 74% to $132 million. Gleevec/Glivec sales were $1.1 billion (+4%). Lucentis sales were $444 million (+22%). Sales of Xolair were up 34% to $107 million. Sales at the Sandoz unit were $2.3 billion (+...